MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer
Metrics: PDF 1554 views | HTML 2200 views | ?
Zibing Wang1,*, Yuqing Liu2,*, Yong Zhang1, Yiman Shang1, Quanli Gao1
1Department of Immunotherapy, Henan Cancer Hospital and Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
2Department of Oncology, Third Affiliated Hospital of Xinxiang Medical College, Xinxiang 453003, China
*These authors contributed equally to this work
Quanli Gao, e-mail: firstname.lastname@example.org
Zibing Wang, e-mail: email@example.com
Keywords: myeloid-derived suppressor cells, cytokine-induced killer cells, immunotherapy, solid tumors, overall survival
Received: June 25, 2015 Accepted: December 12, 2015 Published: December 23, 2015
Adoptive immunotherapy using cytokine-induced killer (CIK) cells is a promising cancer treatment, but its efficacy is restricted by various factors, including the accumulation of myeloid-derived suppressor cells (MDSCs). In this study, we determine whether chemotherapeutic drugs that reduce MDSC levels enhance the efficacy of CIK cell therapy in the treatment of solid tumors. Fifty-three patients were included in this study; 17 were diagnosed with metastatic renal cell carcinoma (MRCC), 10 with advanced pancreatic cancer (PC), and 26 with metastatic melanoma (MM). These patients were divided into two groups: CIK cell therapy alone and CIK cell therapy combined with chemotherapy. Combining CIK cell therapy and chemotherapy increased 1-year survival rates and median survival times in MRCC and PC patients, but not in MM patients. The disease control rate did not differ between treatment groups for MRCC or MM patients, but was higher in PC patients receiving combined treatment than CIK cell treatment alone. These data suggest that addition of MDSC-decreasing chemotherapy to CIK cell therapy improves survival in MRCC and PC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.